Drawing for IO2 INTERVENTIONAL & IMMUNO-ONCOLOGY

USPTO serial 88037659

IO2 INTERVENTIONAL & IMMUNO-ONCOLOGY

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
GOLDEN, LAURA DAWN
Law office
TMEG LAW OFFICE 103

What this means

These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.

Status 602: These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances.

Need help with IO2 INTERVENTIONAL & IMMUNO-ONCOLOGY?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Lori A. Ruhly

Lori A. Ruhly Quarles & Brady LLP33 East Main Street, Suite 900Madison, WI 53703United States

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations and substances for facilitating the delivery of pharmaceutical and medicinal preparations and substances; pharmaceutical preparations and substances for use in the circulatory system; pharmaceutical preparations and substances for embolization; pharmaceutical preparations and substances for embolization of tumours and arteriovenous malformations (AVMs); pharmaceutical preparations and substances for use in the circulatory system for the treatment of tumours and AVMs; adjuvants for medicinal purposes, vaccine adjuvants and vaccine preparations containing adjuvant; chemical reagents for medical purposes; transarterial chemoembolization pharmaceutical preparations, vaccines and sera; irradiated or radioactive microspheres used for in vivo therapeutic medical purposes; radiotherapy substances for medical purposes; radiopharmaceuticals; therapeutic agents for delivery of radioactive material to target sites within the body; radioactive substances for medical purposes, namely, microscopic radioactive beads for treatment of cancerous tumours, microscopic glass beads incorporating radioactive material for treatment of cancerous tumours, and radioactive glass beads; pharmaceutical preparations for use in chemotherapyACTIVE—
010Surgical apparatus and instruments; medical apparatus and instruments for use in the diagnosis and treatment of cancer; Surgical and medical apparatus and instruments, namely, drug delivery systems; apparatus and instruments for embolisation; surgical and medical apparatus and instruments, namely, catheters, injection syringes and sealed vial devices for dispensing microspheres during embolisation procedures in blood vessels and in the circulatory system; embolisation apparatus, instruments and systems comprising surgical and medical instruments for embolisation; drug delivery embolisation systems; drug delivery apparatus and instruments comprised of injection syringes, and sealed vials; injection syringes for use with catheters; apparatus and instruments for use in the circulatory system, namely, catheters, injection syringes and sealed vials; medical apparatus and instruments for embolisation; surgical and medical apparatus and instruments for embolisation, namely, embolisation apparatus, instruments and systems comprising microspheres and injection syringes for use in blood vessels and the circulatory system to carry out embolisation; radiotherapy apparatus; surgical and medical apparatus and instruments for delivery of radiopharmaceuticals and radioactive material to target sites within the body; implantable radiation therapy devices, namely, microscopic glass beads incorporating radioactive material or containing radioactive material and administered surgically for treatment of cancerous tumours, and radioactive glass beads administered for treatment of cancerous tumours; surgical and medical apparatus and instruments for use in the circulatory system; needles for medical use, namely, cannula needles; medical devices for performing cryotherapy, namely, cryosurgical probes and cryoablation needles used for the minimally invasive cryoablation of cancerous tissues; medical apparatus consisting of treatment probes and high pressure valves used for heat or freeze treatment; surgical, medical and medical diagnostic devices, apparatus and instruments for use in cryoablation, and the treatment of prostate cancer, kidney or renal tumours, and benign prostatic hyperplasia (BPH); medical devices used to deliver heat to target sites using electrical current through needles; medical devices to deliver cryogen gas for freezing and either cryogen gas or electrical current for heating; medical devices for ablating human and animal tissue using microwave energy; medical devices for treating cancerous and benign tissue using microwave energy; replacement and structural parts for all of the aforesaid goodsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB2): The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.

DateCodeEventWhat it means
Aug 13, 2025MAB2ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPONDThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Aug 13, 2025ABN2ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSEThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Apr 28, 2025GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 28, 2025GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 28, 2025CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 26, 2025RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION—
Oct 2, 2024TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Oct 2, 2024ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 2, 2024REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Oct 2, 2024CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Oct 2, 2024COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Aug 28, 2024RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Jan 12, 2024RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Jul 15, 2023RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Jul 14, 2023RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Mar 16, 2023CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Mar 16, 2023TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Mar 16, 2023ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 16, 2023REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Mar 16, 2023COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Jan 3, 2023RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Jun 9, 2022RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Dec 9, 2021RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Jun 9, 2021RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Dec 9, 2020RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Aug 30, 2020CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Aug 30, 2020TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Aug 30, 2020EWAFTEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS—
Aug 30, 2020ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Aug 30, 2020REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Aug 30, 2020COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Jun 9, 2020RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Dec 5, 2019GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Dec 5, 2019GNSLLETTER OF SUSPENSION E-MAILED—
Dec 5, 2019CNSLSUSPENSION LETTER WRITTEN—
Dec 4, 2019TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Dec 3, 2019CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Dec 3, 2019TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jul 2, 2019GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 2, 2019GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 2, 2019CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 21, 2019TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
May 21, 2019CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
May 19, 2019ALIEASSIGNED TO LIE—
May 10, 2019TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Nov 20, 2018GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 20, 2018GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 20, 2018CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 31, 2018DOCKASSIGNED TO EXAMINER—
Jul 19, 2018TAEATEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED—
Jul 19, 2018PARITEAS VOLUNTARY AMENDMENT RECEIVED—
Jul 19, 2018MDSMNOTICE OF DESIGN SEARCH CODE E-MAILED—
Jul 18, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jul 17, 2018NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance